B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 432-442

  Mahévas, Matthieu ^a,b   Patin, Pauline ^a   Huetz, François ^a,c   Descatoire, Marc ^a   Cagnard, Nicolas ^d   Bole Feysot, Christine ^a   Gallou, Simon Le ^a   Khellaf, Mehdi ^b   Fain, Olivier ^e   Boutboul, David ^f   Galicier, Lionel ^f   Ebbo, Mikael ^g   Lambotte, Olivier ^h   Hamidou, Mohamed ⁱ   Bierling, Philippe ^b   Godeau, Bertrand ^b   Michel, Marc ^b   Weill, Jean Claude ^a   Reynaud, Claude Agnès ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g HÔPITAL DE LA CONCEPTION   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; CD45 ANTIGEN; CD9 ANTIGEN; CELL CYCLE PROTEIN 6; FIBRINOGEN RECEPTOR ANTIBODY; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 4; KRUPPEL LIKE FACTOR 6; KRUPPEL LIKE FACTOR 9; PROTEIN C JUN; PROTEIN FOS; RECEPTOR ANTIBODY; RITUXIMAB; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLAST CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLEX POLYMERASE CHAIN REACTION; PHENOTYPE; PLASMA CELL; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; SPLEEN CELL; SPLENECTOMY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PLASMA CELLS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLEEN; SPLENECTOMY; TIME FACTORS; TRANSCRIPTOME;

EID: 84873828057     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65689     Document Type: Article

References (47)

1. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997; 388(6638): 133-134.
2. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8(3): 363-372.
3. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19): 1903-1915.
4. Ellyard JI, Avery DT, Phan TG, Hare NJ, Hodgkin PD, Tangye SG. Antigen-selected, immunoglobulin- secreting cells persist in human spleen and bone marrow. Blood. 2004;103(10): 3805-3812.
5. Hoyer BF, et al. Short-lived plasmablasts and longlived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med. 2004; 199(11): 1577-1584.
6. Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3): 170-178.
7. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26): 6511-6521.
8. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006; 133(4): 364-374.
9. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998; 102(7): 1393-1402.
10. Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009;7(2): 322-329.
11. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004; 79(4): 504-522.
12. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004; 104(9): 2623-2634.
13. Godeau B, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008; 112(4): 999-1004.
14. Patel VL, et al. Outcome at 5 years following response to rituximab therapy in children and adults with immune thrombocytopenia (ITP). Blood. 2012;119(25): 5989-5995.
15. Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3): 386-398.
16. Hamaguchi Y, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005;174(7): 4389-4399.
17. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007; 179(5): 3351-3361.
18. Gong Q, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2): 817-826.
19. Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A. 2010;107(10): 4658-4663.
20. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6(5): 394-403.
21. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol. 2010;10(4): 236-247.
22. Mei HE, et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116(24): 5181-5190.
23. Fagerli UM, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111(2): 806-815.
24. Le Y, et al. SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis. Immunity. 2007; 27(5): 811-823.
25. Soriano SF, et al. Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation. J Exp Med. 2002; 196(3): 311-321.
26. Jones SA, White CA, Robb L, Alexander WS, Tarlinton DM. SOCS3 deletion in B cells alters cytokine responses and germinal center output. J Immunol. 2011;187(12): 6318-6326.
27. Ellyard JI, Avery DT, Mackay CR, Tangye SG. Contribution of stromal cells to the migration, function and retention of plasma cells in human spleen: potential roles of CXCL12, IL-6 and CD54. Eur J Immunol. 2005;35(3): 699-708.
28. Audia S, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118(16): 4394-4400.
29. Yoshida T, et al. Memory B and memory plasma cells. Immunol Rev. 2010;237(1): 117-139.
30. Jourdan M, et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 2009;114(25): 5173-5181.
31. Jourdan M, et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011;187(8): 3931-3941.
32. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol Rev. 2010;237(1): 140-159.
33. Hart GT, Hogquist KA, Jameson SC. Kruppel-like factors in lymphocyte biology. J Immunol. 2012; 188(2): 521-526.
34. Good KL, Tangye SG. Decreased expression of Kruppel- like factors in memory B cells induces the rapid response typical of secondary antibody responses. Proc Natl Acad Sci U S A. 2007;104(33): 13420-13425.
35. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A. 2008; 105(12): 4802-4807.
36. Chu VT, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011;12(2): 151-159.
37. Winter O, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood. 2010;116(11): 1867-1875.
38. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 2004;20(6): 707-718.
39. Cassese G, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003;171(4): 1684-1690.
40. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol. 2002;169(8): 4213-4221.
41. Rodriguez Gomez M, Talke Y, Goebel N, Hermann F, Reich B, Mack M. Basophils support the survival of plasma cells in mice. J Immunol. 2010; 185(12): 7180-7185.
42. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004;25(2): 75-84.
43. Iikura M, et al. Transendothelial migration of human basophils. J Immunol. 2004;173(8): 5189-5195.
44. Kreuzaler M, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2012; 188(1): 497-503.
45. Sarantopoulos S, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011;117(7): 2275-2283.
46. Barr TA, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209(5): 1001-1010.
47. Kuwana M, Iki S, Urabe A. The role of autoantibody- producing plasma cells in immune thrombocytopenic purpura refractory to rituximab. Am J Hematol. 2007;82(9): 846-848.